Danny N. Khalil, MD, PhD

About Me

I am a board-certified medical oncologist who specializes in caring for people with hepatobiliary, colorectal, pancreatic, and other gastrointestinal cancers. As a member of the MSK Immunotherapeutics Clinic and the Parker Institute for Cancer Immunotherapy, I am involved in the range of cancer immunotherapy research from basic science to clinical trials.

Read more Read less Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.

With support from the Tri-Institutional Therapeutics Discovery Institute and the MSK Technology Development Fund, my work is largely focused on developing next-generation immunotherapy drugs. By targeting fundamental mechanisms of immune tolerance, these drugs are designed to treat diverse advanced cancers including colon cancer, prostate cancer, liver cancer, and breast cancer

  • Clinical Expertise: Cancer Immunotherapy; Liver Cancer; Cholangiocarcinoma; Gallbladder Cancer; Colon Cancer; Pancreatic Cancer; Other Gastrointestinal Cancers; Development of New Therapies
  • Awards and Honors: American Society of Clinical Oncology Young Investigator Award, Conquer Cancer Foundation; Daland Fellowship in Clinical Investigation, American Philosophical Society; American Association for Cancer Research Amgen Clinical, Translational Cancer Research Fellowship; US Department of Defense, Congressionally Directed Medical Research Programs Prostate Cancer Training Award
  • Languages Spoken: English
  • Education: MD, PhD, Stony Brook University, Cold Spring Harbor Laboratory
  • Residencies: Internal Medicine - NewYork-Presbyterian/Weill Cornell Medical College
  • Fellowships: Medical Oncology - Memorial Sloan Kettering Cancer Center
  • Board Certifications: Internal Medicine, Medical Oncology

My Research

View my lab

See Danny N. Khalil’s laboratory
research at Memorial Sloan Kettering.

Publications

Khalil DN, Smith EL, Brentjens RJ, Wolchok JD. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol. 2016 Jun;13(6):394. doi: 10.1038/nrclinonc.2016.65. Epub 2016 Apr 26.

Khalil DN, Segal NH. Modern Immunotherapy for the Treatment of Advanced Gastrointestinal Cancers. Oncology (Williston Park). 2016 Jan;30(1):85-90, 93. Review.

Read more Read less Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.

Visit PubMed for a full listing of Danny N. Khalil’s journal articles

Pubmed is an online index of biomedical articles maintained by the U.S. National Library of Medicine and the National Institutes of Health.

Clinical Trials

As home to one of the world’s top cancer research centers, Memorial Sloan Kettering is typically involved in more than 900 clinical trials at a given time. Currently, clinical trials focused on the conditions I treat are enrolling new patients. If you’re interested in joining a clinical trial, click to learn about the trial’s purpose, eligibility criteria, and how to get more information.

Learn more

Insurance

Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.

Learn more